Is guselkumab (Tremfya) safe for use in organ transplant patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Guselkumab (Tremfya) Should NOT Be Used in Organ Transplant Patients

Guselkumab is contraindicated or should be avoided in organ transplant recipients due to the risk of serious infections and complications from additional immunosuppression in an already immunocompromised population. The FDA-approved guidelines explicitly state to "use caution in patients with pre-existing immunosuppression-related conditions" 1, and organ transplant recipients fall squarely into this high-risk category.

Why This Matters for Transplant Patients

Organ transplant recipients are maintained on chronic immunosuppressive therapy (typically tacrolimus-based regimens) to prevent graft rejection 2. Adding guselkumab—an IL-23 inhibitor that further suppresses immune function—creates a dangerous compounding effect:

  • Infection Risk: Guselkumab may increase the risk of infections 3. The FDA label specifically warns not to initiate treatment in patients with clinically important active infections 3. Transplant patients already face elevated infection risks, including CMV, bacterial infections, and opportunistic pathogens 4.

  • Immunosuppression Layering: The guideline explicitly advises caution in pre-existing immunosuppression 1. Transplant patients on tacrolimus, mycophenolate, or other agents are already profoundly immunosuppressed—adding guselkumab would intensify this state unpredictably.

  • No Safety Data: There are no published studies evaluating guselkumab safety in transplant recipients. All major trials excluded immunocompromised patients 5.

Clinical Algorithm for Decision-Making

If a transplant patient presents with psoriasis or psoriatic arthritis:

  1. First-line: Use topical therapies, phototherapy, or conventional systemic agents (methotrexate, cyclosporine) that have established safety profiles in transplant populations
  2. If biologics are necessary: Consider agents with more transplant-specific data or consult transplant nephrology/hepatology before initiating any biologic
  3. Absolute avoidance: Do not use guselkumab without compelling evidence of safety in this population

Key Safety Concerns from FDA Labeling

The FDA label warns 3:

  • Serious hypersensitivity reactions including anaphylaxis may occur
  • Evaluate for tuberculosis prior to treatment
  • Avoid live vaccines during treatment
  • Monitor for infections and discontinue if serious infection develops

These warnings are particularly concerning in transplant recipients who:

  • Already require TB screening and prophylaxis
  • Cannot receive live vaccines
  • Have baseline infection susceptibility from maintenance immunosuppression
  • May develop atypical or severe infections more readily

Common Pitfall to Avoid

Do not assume that because guselkumab has a "favorable safety profile" in general populations 6, 7, 8 that it is safe in transplant patients. All published real-world and clinical trial data excluded immunocompromised individuals. The 94% drug survival rate at 93 weeks 8 and excellent safety in TNF-experienced patients 9 apply only to immunocompetent psoriasis patients, not those on chronic transplant immunosuppression.

The risk-benefit calculation fundamentally changes when baseline immune function is already compromised. Prioritizing graft survival and preventing life-threatening infections must take precedence over treating psoriasis in this population.

References

Research

Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.